TP53 and endometrial cancer: Adding to that is data of a small cohort (n = 15) analyzed by Falcone et al. [66], reporting in their analysis of biopsy samples of young women with endometrial cancer, that 46.7% were MMR abnormal, 6.6% POLE EDM, 0% p53 abnormal and 46.7% p53 wild type [66].